The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class ...
It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.
( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
The U.S. Food and Drug Administration has approved Journavx (suzetrigine) 50 milligram oral tablets, marking the introduction of a first-in-class non-opioi ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVXâ„¢ (suzetrigin ...
The U.S. Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals (NASDAQ:VRTX) non-opioid drug Journavx for acute pain, marking a breakthrough in pain management. Unlike traditional ...
Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), boosting the price target to ...